HR Stock Analysis: Healthcare Realty Trust | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 7.506m USD | 12M Return: 45% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 71.6M
Qual. Beats: 1
Rev. Trend: -95.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Healthcare Realty Trust Incorporated (NYSE: HR) is a healthcare-focused real estate investment trust (REIT) that owns and operates medical outpatient buildings primarily situated around market-leading hospital campuses. The company grows its portfolio through both property acquisitions and development, and as of September 30, 2025, it held investments in 579 real estate properties across 28 states, totaling 33.6 million square feet, with an enterprise value of approximately $11.1 billion.
Headquartered in Nashville, Tennessee and incorporated in 1992, Healthcare Realty Trust is classified within the GICS Health Care REITs sub-industry and trades as a mid-cap stock with a market capitalization of approximately $6.94 billion. As a REIT, the company is generally required to distribute the majority of its taxable income to shareholders in the form of dividends, a structural feature that distinguishes it from conventional real estate operators. Its focus on outpatient medical facilities-rather than hospitals or skilled nursing-places it in a specialized segment of healthcare real estate that typically benefits from long-term tenant leases with health systems and physician groups.
- Outpatient care shift boosts medical office building demand
- Rising interest rates pressure cap rates and acquisition pace
- Same-store NOI growth driven by rent escalators and occupancy gains
| Net Income: -201.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.43 > 1.0 |
| NWC/Revenue: -0.14% < 20% (prev -16.68%; Δ 16.54% < -1%) |
| CFO/TA 0.05 > 3% & CFO 462.2m > Net Income -201.3m |
| Net Debt (4.55b) to EBITDA (541.8m): 8.40 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (347.4m) vs 12m ago -0.60% < -2% |
| Gross Margin: -8.58% > 18% (prev -42.15%; Δ 33.57% > 0.5%) |
| Asset Turnover: 11.82% > 50% (prev 11.82%; Δ -0.00% > 0%) |
| Interest Coverage Ratio: -0.06 > 6 (EBIT TTM -12.0m / Interest Expense TTM 190.1m) |
| A: -0.00 (Total Current Assets 149.6m - Total Current Liabilities 151.3m) / Total Assets 9.15b |
| B: -0.50 (Retained Earnings -4.60b / Total Assets 9.15b) |
| C: -0.00 (EBIT TTM -12.0m / Avg Total Assets 9.82b) |
| D: 0.95 (Book Value of Equity 4.44b / Total Liabilities 4.65b) |
| Altman-Z'' = -0.65 = B |
As of July 29, 2026, the stock is trading at USD 21.53 with a total of 2,951,585 shares traded. Over the past week, the price has changed by +1.32%, over one month by +4.31%, over three months by +18.55% and over the past year by +44.95%.
Current recommended Stop Loss: 21.00 (which is 2.5% or 1.4 ATR below the current price).
Healthcare Realty Trust has received a consensus analysts rating of 3.45. Therefore, it is recommended to hold HR.
- StrongBuy: 2
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.3 | -0.9% |
P/E Forward = 10.8342
P/S = 6.4659
P/B = 1.6705
P/EG = 8.8222
Revenue TTM = 1.16b USD
EBIT TTM = -12.0m USD
EBITDA TTM = 541.8m USD
Long Term Debt = 3.80b USD (from longTermDebt, last quarter)
Short Term Debt = 236.1m USD (from shortTermDebt, last quarter)
Debt = 4.58b USD (from shortLongTermDebtTotal, last quarter) + Leases 236.1m
Net Debt = 4.55b USD (calculated: Debt 4.58b - CCE 26.2m)
Enterprise Value = 12.1b USD (7.51b + Debt 4.58b - CCE 26.2m)
Interest Coverage Ratio = -0.06 (Ebit TTM -12.0m / Interest Expense TTM 190.1m)
EV/FCF = 86.11x (Enterprise Value 12.1b / FCF TTM 140.0m)
FCF Yield = 1.16% (FCF TTM 140.0m / Enterprise Value 12.1b)
FCF Margin = 12.06% (FCF TTM 140.0m / Revenue TTM 1.16b)
Net Margin = -17.34% (Net Income TTM -201.3m / Revenue TTM 1.16b)
Gross Margin = -8.58% ((Revenue TTM 1.16b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 64.14% (prev -27.68%)
Tobins Q-Ratio = 1.32 (Enterprise Value 12.1b / Total Assets 9.15b)
Interest Expense / Debt = 4.15% (Interest Expense 190.1m / Debt 4.58b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -9.47m (EBIT -12.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.99 (Total Current Assets 149.6m / Total Current Liabilities 151.3m)
Debt / Equity = 1.03 (Debt 4.58b / totalStockholderEquity, last quarter 4.44b)
Debt / EBITDA = 8.40 (Net Debt 4.55b / EBITDA 541.8m)
Debt / FCF = 32.50 (Net Debt 4.55b / FCF TTM 140.0m)
Total Stockholder Equity = 4.64b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.05% (Net Income -201.3m / Total Assets 9.15b)
RoE = -4.34% (Net Income TTM -201.3m / Total Stockholder Equity 4.64b)
RoCE = -0.14% (EBIT -12.0m / Capital Employed (Equity 4.64b + L.T.Debt 3.80b))
RoIC = -0.10% (negative operating profit) (NOPAT -9.47m / Invested Capital 9.21b)
WACC = 5.35% (E(7.51b)/V(12.1b) * Re(6.61%) + D(4.58b)/V(12.1b) * Rd(4.15%) * (1-Tc(0.21)))
Discount Rate = 6.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.08 | Cagr: -3.80%
[DCF] Terminal Value 73.10% ; FCFF base≈166.2m ; Y1≈145.8m ; Y5≈117.8m
[DCF] Fair Price = N/A (negative equity: EV 1.89b - Net Debt 4.55b = -2.66b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.53 | # QB: 1
Revenue Correlation: -95.59 | Revenue CAGR: -5.45% | SUE: -0.29 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.02 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.03 | Chg30d=+53.92% | Revisions=+0% | GrowthEPS=+96.0% | GrowthRev=-4.9%
EPS next Year (2027-12-31): EPS=0.02 | Chg30d=+150.00% | Revisions=+25% | GrowthEPS=+9.1% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +25% (up=1, down=0)